• Login
    View Item 
    •   Home
    • The Christie Research Publications Repository
    • All Christie Publications
    • View Item
    •   Home
    • The Christie Research Publications Repository
    • All Christie Publications
    • View Item
    JavaScript is disabled for your browser. Some features of this site may not work without it.

    Browse

    All of ChristieCommunitiesTitleAuthorsIssue DateSubmit DateSubjectsThis CollectionTitleAuthorsIssue DateSubmit DateSubjects

    My Account

    LoginRegister

    Local Links

    The Christie WebsiteChristie Library and Knowledge Service

    Statistics

    Display statistics

    Phase I study of the combination of the dual RAF/MEK inhibitor VS-6766 and the FAK inhibitor defactinib: Results of efficacy in low grade serous ovarian cancer

    • CSV
    • RefMan
    • EndNote
    • BibTex
    • RefWorks
    Thumbnail
    Name:
    AnnOncBanerjee.pdf
    Size:
    73.52Kb
    Format:
    PDF
    Description:
    From UNPAYWALL
    Download
    Authors
    Banerjee, S.
    Grochot, R.
    Shinde, R.
    Lima, J.
    Krebs, Matthew G
    Rahman, Rozana A
    Little, Martin
    Tunariu, N.
    Curcean, A.
    Badham, H.
    Mahmud, M.
    Turner, A.
    Parmar, M.
    Yap, C.
    Minchom, A.
    Lopez, J.
    de Bono, J.
    Banerji, U.
    Show allShow less
    Affiliation
    Gynaecology Unit, The Royal Marsden NHS Foundation Trust, Sutton, UK
    Issue Date
    2021
    
    Metadata
    Show full item record
    Abstract
    Background Patients with low grade serous ovarian cancer (LGSOC) have limited response to conventional chemotherapy and hormonal therapy. Recently, MEK inhibitors have shown an overall response rate (ORR) 15-26%. Activation of p-FAK is a possible mechanism of resistance to MEK inhibitors and we hypothesised combination of a RAF/MEK inhibitor with a FAK inhibitor would overcome this. Methods We explored the safety, pharmacokinetics and pharmacodynamics in the dose escalation study and recommended a phase two dose of the combination of RAF/MEK inhibitor VS-6766 3.2 mg twice a week and the FAK inhibitor defactinib 200 mg twice daily, both administered 3 out of 4 weeks in 28 day cycles in a highly intermittent dosing schedule. We evaluated confirmed responses using RECIST 1.1. We present the efficacy of the combination in patients with LGSOC in this trial so far. Results Currently, 25 patients with LGSOC have been treated with 24 evaluated for response, median age 57 (range 31 to 75 years) and median previous lines of therapy 4 (range 1 to 9). Of the 24 evaluable patients, 11 (46%) had KRAS mutations and 10 (42%) received prior MEK inhibitor treatment. The most common adverse events were rash and CK elevation which were predominantly grade 1/2. The overall response rate in all patients was 46% (11/24, 95% CI: 28% to 65%), with ORR of 64% (7/11, 95% CI: 35% to 85%) in patients with KRAS mutations, and 44% (4/9, 95% CI: 19% to 73%) in patients with KRAS wildtype tumours. Four patients had undocumented KRAS status. Responses were observed in patients with and without prior MEK inhibitor treatment. The median progression free survival was 23 months for the whole cohort, 13/24 patients are still on study and updated results will be presented. Conclusions An intermittent dosing schedule of the combination of VS-6766 and defactinib has shown encouraging clinical activity in patients with recurrent LGSOC. These data support an ongoing registration-directed study of VS-6766 � defactinib in patients with recurrent LGSOC (ENGOT-ov60/NCRI/GOG-3052; NCT04625270).
    Citation
    Banerjee S, Grochot R, Shinde R, Lima J, Krebs M, Rahman R, et al. 725MO Phase I study of the combination of the dual RAF/MEK inhibitor VS-6766 and the FAK inhibitor defactinib: Results of efficacy in low grade serous ovarian cancer. Vol. 32, Annals of Oncology. Elsevier BV; 2021. p. S728.
    Journal
    Annals of Oncology
    URI
    http://hdl.handle.net/10541/624713
    DOI
    10.1016/j.annonc.2021.08.1168
    Additional Links
    https://dx.doi.org/10.1016/j.annonc.2021.08.1168
    Type
    Other
    Language
    en
    ae974a485f413a2113503eed53cd6c53
    10.1016/j.annonc.2021.08.1168
    Scopus Count
    Collections
    All Christie Publications

    entitlement

     
    DSpace software (copyright © 2002 - 2023)  DuraSpace
    Quick Guide | Contact Us
    Open Repository is a service operated by 
    Atmire NV
     

    Export search results

    The export option will allow you to export the current search results of the entered query to a file. Different formats are available for download. To export the items, click on the button corresponding with the preferred download format.

    By default, clicking on the export buttons will result in a download of the allowed maximum amount of items.

    To select a subset of the search results, click "Selective Export" button and make a selection of the items you want to export. The amount of items that can be exported at once is similarly restricted as the full export.

    After making a selection, click one of the export format buttons. The amount of items that will be exported is indicated in the bubble next to export format.